CD38 and Miyoshi myopathy: Daratumumab, a monoclonal anti-CD38 antibody approved for the treatment of multiple myeloma (MM) [72,73], was shown to block the delivery of mitochondria to AML cells under both in vitro and in vivo conditions, decrease the oxygen consumption rate (OCR), and inhibit the growth of leukemic cells [74,75].